Genfit Investor Relations Material
Latest events
H1 2023
Genfit
Q1 2025
22 May, 2025
Q4 2024
24 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Genfit S.A.
Access all reports
Genfit S.A. is a biopharmaceutical company focused on discovering and developing innovative therapeutic and diagnostic solutions in the areas of liver-related diseases and metabolic disorders. The company specializes in creating proprietary drug candidates and biomarkers to address unmet medical needs, particularly in non-alcoholic steatohepatitis (NASH) and other chronic liver conditions. Genfit's portfolio includes both therapeutic and diagnostic assets aimed at improving patient outcomes through targeted treatment strategies and precision medicine. The company is headquartered in Loos, France, and its shares are listed on the Euronext Paris.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
GNFT
Country
🇫🇷 France